University of Nebraska

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Nebraska sits in the top decile of US sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count).

407 total trials 51 currently recruiting 261 completed early-phase tilt top decile by trial count

University of Nebraska: 407 sponsored US clinical trials, 51 recruiting.

University of Nebraska sponsors 407 registered US clinical trials on ClinicalTrials.gov, 51 of them currently recruiting, and 261 completed. 31 of these trials are in Phase 3-4 (later-stage) and 109 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Peripheral Arterial Disease, with 7 trials.

Top-decile sponsor footprint

University of Nebraska ranks in the top decile of sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 36/100

261 of 332 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

407 total, page 9 of 9

COMPLETED Phase 2

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

NCT00004197
COMPLETED Phase 2

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma

NCT00004198
TERMINATED Phase 3

Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

NCT00004874
COMPLETED Phase 1

Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma

NCT00572013
COMPLETED Phase 1

Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma

NCT00574509
COMPLETED Phase 2

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia

NCT00002638
COMPLETED NA

Comparing Autologous Peripheral Blood Stem Cell to Bone Marrow Transplantation for Recurrent Non-Hodgkin's Lymphoma

NCT00574626
← Previous Page 9 of 9

Phase Distribution

PhaseTrial count
Phase 1 57
Phase 2 52
Phase 3 10
Phase 4 21

Therapeutic Areas

Peripheral Arterial Disease 7
Lymphoma 6
Breast Cancer 5
Rheumatoid Arthritis 5
Peripheral Artery Disease 3
Multiple Myeloma 3
Healthy 3
Sleep Fragmentation 2
Graft-versus-host Disease (GVHD) 2
Parkinson's Disease 2

What is open in the University of Nebraska pipeline

51 recruiting of 407 indexed (13% open); 261 completed (64%).

Phase mix: 31 late (III/IV) vs 109 early (I/II) (early-phase heavy).

Top condition: Peripheral Arterial Disease (7 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Nebraska: open-pipeline peers nationwide

Peers matched on 407 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

University of Nebraska sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 10%15%20%25% Total trials Recruiting share University of NebraskaCase Comprehensive Cancer CenterTakedaUniversity of Kansas Medical CenterSt. Jude Children's Research HospitalAddario Lung Cancer Medical InstituteAmerican UniversityAnnexonAnsun Biopharma
University of Nebraska sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Nebraska sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 407 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of Nebraska page

407 registered trials is a research-attention snapshot, not an endorsement of University of Nebraska or any single study.

  • 51 of University of Nebraska's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Peripheral Arterial Disease is the condition University of Nebraska studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Peripheral Arterial Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Nebraska pipeline card: 407 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.